GLOW2 Phase 3: Tarcocimab for Diabetic Retinopathy
Key Questions
What are the key results from the GLOW2 Phase 3 trial?
The GLOW2 trial showed that tarcocimab achieved a 62.5% rate of ≥2-step improvement in Diabetic Retinopathy Severity Scale (DRSS) compared to sham. It also demonstrated an 85% reduction in complications and supports 6-month dosing intervals.
What is tarcocimab and what conditions is it targeting?
Tarcocimab is Kodiak Sciences' therapy for diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR), and diabetic macular edema (DME). The Phase 3 GLOW2 trial highlighted its efficacy in improving DR severity with extended dosing.
What are the next steps for tarcocimab following GLOW2?
Kodiak Sciences plans to submit a Biologics License Application (BLA) to the US FDA imminently based on the positive GLOW2 results. This advances its potential approval for DR, PDR, and DME treatments.
Kodiak reports 62.5% ≥2-step DRSS improvement vs sham, 85% reduction in complications, 6-month dosing; BLA filing imminent for DR/PDR/DME advance.